Avivagen Inc VIVXF

RE:Some Fact to Go with the Hype now.

[Delmic]

This study although simple in the way it was designed is effective in showing the potential of OxC-beta in stimulating the primary immune response. 

To keep it simple the study suggests that it preps cells from the innate immune response such as monocytes and gets them ready should they need to be further activated upon an immune challenge (such as LPS coming from bacterial cell wall).

It also preps them in a way that is not overly stimulated, thus keeping low the risk of adverse reactions related to immune system hyperstimulation. Most importantly, alone, it does not activate these cells.

Of course, now that they have checked the in vitro validation it will be important to show the same in animal models and eventually in a large clinical trial with human subjects. The company could still start with humans and simply collect peripheral blood mononuclear cells (by a venous puncture), plate them and perform similar in vitro analysis to what was done in this article. Maybe this is already on its way... we shall see.